CEL-SCI Corporation (CVM) Quarterly EPS earnings growth
The quarterly EPS growth index on GURU.Markets demonstrates the impact of patent monopoly on profitability, creating sustainable clinical inertia for CEL-SCI Corporation (CVM). This chart shows that 65.40 represents the latest level value. The business relies on the Multikine system to update oncology treatment standards; however, a strict focus on a single product creates binary risk dependent on the FDA verdict.
%20Year-over-year%20net%20earnings%20per%20share%20growth%20for%20the%20last%2012%20months&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_CVM_-_CEL-SCI-Corporation_-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "CEL-SCI Corp (CVM) Quarterly EPS earnings growth: for the period 07/04/2022 - 11/15/2026 | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for CEL-SCI (CVM)
- share price and expert price forecast:
- market capitalization details:
- balance sheet net asset value indicators:
- debt and liquidity details:
Total Debt to Equity Ratio CEL-SCI Corporation|CVM - Long-Term Indebtedness to Equity|Short-Term Debt to Equity CEL-SCI Corporation|CVM - Company Total Debt Obligations|Debts to Book Capitalization CEL-SCI Corporation|CVM - Company Long-Term Liabilities|Company Short-Term Debts CEL-SCI|Quick Liquidity Indicator cel-sci.com
- earnings and valuation multiples indicators:
CVM - Final Profit|Projected Future Earnings CEL-SCI Corporation|CVM - Price to Earnings Ratio|Future Price to Earnings cel-sci.com|CVM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CEL-SCI Corporation|CVM - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months CEL-SCI|CVM - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months cel-sci.com|CVM - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year CEL-SCI Corporation
- sales volume and revenue indicators:
Analysis of all company metrics:cel-sci.com - CVM
CEL-SCI Corporation (CVM) is developing an immune activation system by integrating the drug Multikine into oncology protocols to combat head and neck tumors. Quarterly earnings per share (EPS) dynamics allow for an assessment of the business's financial recovery pace, while analyzing quarterly EPS variability helps investors avoid overpaying during speculative growth or capital stagnation during a prolonged downturn.
Main competitors
ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth in annualized terms for the last twelve months|Erasca Oncology - Quarterly EPS earnings growth|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|Aura Bio (AURA) - Quarterly EPS earnings growth|CADL (Candel Therapeutics Inc.) - Quarterly EPS earnings growth|ARAY: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SLS (SELLAS Life Sciences Group, Inc.)|Year-over-year earnings per share growth rate for the last twelve months ACTU|Citius Oncology - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HURA|TARA: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Fate Pharma|Aadi Bioscience Inc (WHWK) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months TScan (TCRX)|Year-over-year net earnings per share growth for the last 12 months CSBR|xbiotech.com (XBIT) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth OSTX|RADX (Radiopharm Theranostics Limited) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ARTV (Artiva Biotherapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months ANL|VERU: Year-over-year net earnings per share growth for the last 12 months|TPST - Quarterly EPS earnings growth|XLO (xiliotx.com) - Year-over-year net earnings per share growth for the last 12 months|Renovaro Biosciences - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months MURA|Year-over-year earnings per share growth for the last twelve months KAPA|Year-over-year net earnings per share growth for the last 12 months OKUR (OnKure Therapeutics Inc)|Quarterly EPS earnings growth CytoMed (GDTC)|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)
